David A Hagelstein Net Worth

The estimated Net Worth of David A Hagelstein is at least $5.69 Million dollars as of 27 August 2012. David Hagelstein owns over 7,000 units of Rockwell Medical Inc stock worth over $5,578,870 and over the last 15 years David sold RMTI stock worth over $111,800.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Hagelstein RMTI stock SEC Form 4 insiders trading

David has made over 24 trades of the Rockwell Medical Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently David bought 7,000 units of RMTI stock worth $56,700 on 27 August 2012.

The largest trade David's ever made was buying 71,000 units of Rockwell Medical Inc stock on 24 November 2010 worth over $553,800. On average, David trades about 13,679 units every 40 days since 2009. As of 27 August 2012 David still owns at least 1,360,700 units of Rockwell Medical Inc stock.

You can see the complete history of David Hagelstein stock trades at the bottom of the page.

What's David Hagelstein's mailing address?

David's mailing address filed with the SEC is 36801 WOODWARD AVE, STE 313, BIRMINGHAM, MI, 48009.

Insiders trading at Rockwell Medical Inc

Over the last 21 years, insiders at Rockwell Medical Inc have traded over $3,082,721 worth of Rockwell Medical Inc stock and bought 689,891 units worth $3,959,861 . The most active insiders traders include Robert L Chioini, David S.Rbi Private Investm..., and Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of $170,433. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth $43,724.

What does Rockwell Medical Inc do?

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www

Complete history of David Hagelstein stock trades at Rockwell Medical Inc

Rockwell Medical Inc executives and stock owners

Rockwell Medical Inc executives and other stock owners filed with the SEC include:

• Raymond Pratt,
  Chief Development Officer
• Ajay Gupta,
  Chief Scientific Officer
• Dr. Russell H. Ellison M.Sc., M.D., MSc.,
  Pres, CEO & Director
• Dr. Raymond Dennis Pratt FACP, M.D.,
  Chief Devel. Officer
• Russell L. Skibsted M.B.A.,
  Exec. VP, CFO & Chief Bus. Officer
• John Cooper,
  Independent Director
• Mark Ravich,
  Independent Director
• John McLaughlin,
  Independent Chairman of the Board
• Robert Radie,
  Independent Director
• Marc Hoffman,
  Chief Medical Officer
• Michael DeYoung,
  Vice President - Operations
• Paul McGarry,
  Principal Accounting Officer, Vice President, Corporate Controller
• Jim McCarthy,
  Senior Vice President - Corporate and Business Development
• Russell Skibsted,
  Executive Vice President, Chief Financial Officer and Chief Business Officer
• Russell Ellison,
  President, Chief Executive Officer, Director
• David J. Kull,
  Sec.
• Dr. Marc L. Hoffman,
  Chief Medical Officer
• Timothy T. Chole,
  Sr. VP of Sales & Marketing
• Megan C. Timmins,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Paul E. McGarry,
  VP, Corp. Controller & Principal Accounting Officer
• Tim Chole,
  VP of Marketing
• Anne Boardman,
  VP of Sales and Strategic Accounts
• James A. McCarthy,
  Sr. VP of Bus. & Corp. Devel.
• Michael Costello,
  Gen. Counsel
• David S.Rbi Private Investm...,
  
• Patrick J Bagley,
  Director
• Ronald D Boyd,
  Director
• Robin L Smith,
  Director
• Kenneth L Holt,
  Director
• Allen Nissenson,
  Director
• Stuart M Paul,
  Chief Executive Officer
• Brothers, Inc.Richmond Davi...,
  
• Benjamin Wolin,
  Director
• Lisa N Colleran,
  Director
• Mark H Ravich,
  Director
• David Kull,
  Principal Accounting Officer
• David S.Rbi Private Investm...,
  
• Angus W. Smith,
  Chief Financial Officer
• David S.Rbi Private Investm...,
  
• Mark Strobeck,
  President and CEO
• David A Hagelstein,
  10% owner
• Annamaria T Kausz,
  VP of Drug Development
• Robert L Chioini,
  Chairman, President and CEO
• Richard C Yocum,
  VP - Clin. Dev. & Med. Affairs
• Thomas E Klema,
  Vice President, CFO
• Megan C. Timmins,
  EVP, CLO and Secretary
• David S.Rbi Private Investm...,
  
• Joan Lau,
  Director
• Jesse Neri,
  SVP, FINANCE